PasqualeFNesticoMD

PubMed

• 26 citations
  Relative prognostic value of rest thallium-201 imaging, radionuclide ventriculography and 24 hour ambulatory electrocardiographic monitoring after acute myocardial inf...
  A-Hamid Hakki, Pasquale F. Nestico, Jaekyeong Heo, Ashfaque A. Unwala, Abdulmassih S. Iskandrian
  Journal of the American College of Cardiology. 1987-07-01
• 16 citations
  Predicting success of intensive dialysis in the treatment of uremic pericarditis.
  Nicholas L. De Pace, Pasquale F. Nestico, Allan B. Schwartz, Gary S. Mintz, J. Sanford Schwartz
  The American Journal of Medicine. 1984-01-01
• 105 citations
  Mitral annular calcification: clinical, pathophysiology, and echocardiographic review.
  Pasquale F. Nestico, Nicholas L. DePace, Joel Morganroth, Morris N. Kotler, John Ross
  American Heart Journal. 1984-05-01

Journal Articles

• Left Ventricular injury and syncope due to Pulmonary Embolism in a soldier: Normal Coronaries and novel pathologic ECG signs  
  Nestico PF, Cassimatis DC, Sheikh F, Huber M, Davison J, Modlin R, Military Medicine, 1/1/2008
• Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: A report from the ALLHA...  
  Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN, for the ALLHAT Collaborative Res..., J Clin Hypertens, 1/1/2004
• The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease  
  Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C, for the ALLHAT Collaborative Research Group, Arch Intern Med, 1/1/2004
• Characteristics and lipid distribution of a large, high-risk, hypertensive population: The lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatmen...  
  Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reison E, Sumner BM, Wong ND, Nwachuku C, Narayan P, Haywood LJ, Habib G, for the ALLHAT Collabor..., J Clin Hypertens, 1/1/2003
• Diuretic versus Beta-blocker as first-step antihypertensive therapy Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ...  
  ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Hypertension, 1/1/2003
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive an...  
  The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (Nestico PF), JAMA, 1/1/2002
• Validation of heart failure events in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and c...  
  Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Jr, Williamson JD, Leenen FHH, Einhorn PT, Randall OS, Golden JS, Haywood LJ, for the ALLHAT Collaborative Resea..., Current Controlled Trials in Cardiovascular Medicine, 1/1/2002
• Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or c...  
  Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD, for the ALLHAT Collaborative Research Group (Nestico PF), Ann Intern Med, 1/1/2002
• Baseline characteristics of the 42,448 high-risk hypertensives enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)  
  Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Echfeldt J, Hawkins CM, Proschan M, for the ..., Hypertension, 1/1/2001
• Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)  
  Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS, for the ALLHAT Collaborative Research Group (Nestico PF), Diabetes Care, 1/1/2001
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience  
  Wright JT, Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FHH, Frolkis J, Letterer R, Walsh S, Tobin JN, Deger GE, for..., Controlled Clinical Trials, 1/1/2001
• Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)  
  Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lush C, Parks H, Simpson LM, Nwachuku C, Furberg CD, for the ALLHAT ..., Controlled Clinical Trials, 1/1/2001
• Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)  
  Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H, for the ALLHAT Research Group (Nestico PF), Controlled Clinical Trials, 1/1/2001
• ALLHAT and calcium channel blockers  
  Proschan M, Davis B, Cutler J, Ford C, Furberg, C, Grimm R, Oparil S, for the ALLHAT Research Group, Am J Hypertension, 1/1/1997
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atta...  
  The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (Nestico PF), JAMA, 1/1/1996
• Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to prevent heart attack trial (ALLHAT)  
  Davis BR, for the ALLHAT Research Group (Nestico PF), American J. Hypertension, 1/1/1996
• Ventricular Disarrhythmias: Diagnosis and treatment  
  Nestico PF, Hospital Medicine, 1/1/1990
• Tricuspid regurgitation  
  Nestico PF, Morganroth J, McGinn C, Primary Cardiology, 1/1/1989
• Flail mitral valve Manifestations and natural history  
  Nestico PF, DePace NL, Primary Cardiology, 1/1/1989
• New Antiarrhythmic drugs  
  Nestico PF, Morganroth J, Horowitz LN, DRUG, 1/1/1988
• Treatment of resistant Ventricular Tachycardia with Encainide Hydrochloride  
  The Encainide-Ventricular Tachycardia Study Group (Nestico PF), Am J Cardiol, 1/1/1988
• Propafanone: A new Antiarrhythmic Drug  
  Nestico PF, Am Family Physician, 1/1/1988
• Relative prognostic value of rest thallium-201 imaging, radionuclide ventricullography and 24 hour Ambulatory Electrocardiographic monitoring after acute myocardial in...  
  Hakki AH, Nestico PF, Heo J, et al, J Am Col Cardiol, 1/1/1987
• Antiarrhythmic agents for chronic ventricular arrhythmias Current Concepts  
  Nestico PF, Morganroth J, Comprehensive Therapy, 1/1/1987
• Effects of beta-blockade on systolic and diastolic left ventricular function at rest and during exercise in patients with chronic stable angina pectoris  
  Iskandrian AS, Nestico PF, Hakki AH, et al, Am Heart J, 1/1/1987
• Join now to see all

Books/Book Chapters

• Modern Coronary Care 
  Chapter: Ambulatory monitoring after myocardial infarction. 
  Page 653 - 655Nestico PF, Morganroth JEditors: Gary S. Francis and Joseph S. Alpert.Little, Brown and Company1990
• Emergency in Cardiology 
  Chapter: Sudden Cardiac Death. 
  Page 198 - 206Nestico PF, Morganroth JEditors: Dereck J. Rowlands.John Wright and Sons Ltd., Hertfordshire, England1989
• Cardiovascular Clinics 
  Chapter: Congestive Heart Failure and ventricular arrhythmias. 
  Nestico PF, Morganroth JEditors: Albert Brest, Jefferson.1988
• The pathophysiology and pharmacotherapy of myocardial infarction. 
  Chapter: The pharmacology of antiarrhythmic drugs. 
  Page 241 - 268Nestico PF, Morganroth JEditors: N. El-Sherif and CV Ramana Reddy.Academy Press, Inc., New York, NY1986
• Cardiology 
  Chapter: Ambulatory Holter Electrocardiography: Technology, Clinical Applications and Limitations. 
  Morganroth J, Nestico PFEditors: William W. Parmley and Kanu Chatterjee.J.B. Lippincott Company, Philadelphia, PA1986
• Sudden Cardiac Death 
  Chapter: Experimental antiarrhythmic drugs. 
  Page 191 - 247Morganroth J, Nestico PF, Horowitz LNEditors: J. Morganroth and LN Horowitz.Grune & Stratton, Inc., Orlando, FL1985
• Join now to see all

Abstracts/Posters

• Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prehvent Heart Attack Trial (ALLHAT).
  Ford CE, Margolis KL, Piller L, Cushman WC, Wright JT, Colon PJ, for the ALLHAT Collaborative Research Group, 15th Scientific Meeting of the Inter-American Society of Hypertension, San Antonio, TX, 1/27/2003
• Cardiovascular Disease (CVD) outcomes in hypertensive patientswith impaired renal function.
  Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group, National Kidney Foundations Clinical Meetings, Dallas, TX, 1/2/2003
• Renal outcomes in hypertensive patients with impaired renal function.
  Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group, National Kidney Foundations Clinical Meetings, Dallas, TX, 1/2/2003
• Review of heart failure events in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Heart Failure Validation Study.
  Einhorn P, Davis B, Piller L, deLeon B, Simpson L, Kostis J, Levy D, Massie B, Nwachuku C, Black H, Cushman W, for the ALLHAT Collaborative Research Group, Circulattihon; 76th Annual Scientific Sessions of the American Heart Association, Orlando, FL, 1/1/2003
• Baseline Characteristics of ALLHAT participants with impaired renal function; association with cardiovascular disease.
  Rahman M, Brown C, Coresh J, Eckfeldt J, Jelley M, Kopyt N, Levey A, Pressel S, Reisin E, Walworth C, Davis B and the ALLHAT Collaborative Research Group, Am J Hytpertension; 17th Annual Meeting of the American Society of Hypertension, New York, NY, 1/1/2002
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: Preliminary restults from ALLHAT.
  The ALLHAT Collaborative Research Group, 49th Annual Scientific Session of the American College of Cardiology, Late-breaking clinical trials in Interventional Cardiology (#72), Anaheim, CA, 1/15/2000
• Clinical center recruitment experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
  Davis BR, Pressel S, Wright J, Cushman W, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Leenen F, Frolkis J, Letterer R, Walsh S, Tobin J, Deger G, for the ALLHA..., Control led Clinical Trials; 21st Annual Meeting of the Society for Clinical Trials, Toronto, Ontario, Canada, 1/1/2000
• Cardiovascular disease rates in Hispanic and Caribbean hypertensives receiving doxazosin and chlorthalidone in the ALLHAT.
  Colon PJ, Wright JT, Ford CE, Cuttler JA, for the ALLHAT Collaborative Research Group, Ethnicity and Disease; Joint Meteting of the International Society for Hypertension in Blacks and the 15th Annual Interdisciplinary Conference on Hypertension and Related Risk Factors in Ethnic Populations, Las Croabas, Puerto Rico, 1/1/2000
• ALLHAT Adherence Survival Kit.
  Lusk CM, Egan D, Carroll L, Kingry C, Johnson JM, Sullivan S, Probstfield J for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, Controlled Clinical Trials; 20th Annual Meeting of the Society for Clinical Trials, Anaheim, CA, 1/1/1999
• Racial differences in blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
  Margolis KL, Cushman WC, Wright JT, Grimm RH, Ford CE, Cutler JA for the ALLHAT Research Group, J General Internal medicine; 22 nd Annual Meeting of the Society for General Internal Medicine, San Francisco, CA, 1/1/1999
• Atrial fibrillation in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) clinical trial at baseline.
  Haywood LJ, Crow R, Ford C, for the ALLHAT Research Group, Ethnicity and Disease; 14th International Interdisciplinary Conference on Hypertension in Blacks, Toronto, Ontario, Canada, 1/1/1999
• ALLHAT: The largest clinical trial in hypertension ever undertaken.
  Davis BR, Hawkins CM, Cutler, JA, Payne G, Ford CE, Pressel S, Gordon D, Nwachuku C, Wright J, Cushman W, Grimm R for the ALLHAT Research Group, 6th International Symposium on Hypertension in the Community: Screening, Investigation, and Therapy, Geneva, Switzerland, 1/8/1998
• Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
  Cushman WC, Black HR, Probstfield JL, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE, Payne GH, Ford CE for the ALLHAT Research Group, Am J Hypertension; 13th Scientific Meeting of the American Society of Hypertension, New York, NY, 1/1/1998
• Visit (Vad) and Medication (Mad) adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Effect of age and other factors.
  Nwachuku CE, Probstfield JL, Ford CE, Payne GH, Grimm RH for the ALLHAT Research Group, Am J Hypertension; 13th Scientific Meeting of the American Society of Hypertension, New York, NY, 1/1/1998
• The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT); Design, recruitmhent experience and baseline characteristics.
  Papademetriou V, Grimm KH, Jr, for the ALLHAT Research Group, 4th International Symposium on Multiple Risk Factors in Cardiovascular Disease, Washington, DC, 1/23/1997
• Characteristics of the diabetic cohort in the ALLHAT study.
  Barzilay J, Jordan J, Grimm R, Davis B, Oparil S, and the ALLHAT investigators, Hypertension; 12th Scientific Meeting of the Inter-American Society of Hypertension, San Francisco, CA, 1/1/1997
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Recruitment update and baselinetdata.
  Wright JT, Jr, Cutler JA, Davis BR, Cushman WC, Pressel S, for the ALLHAT Research Group, 11th International Interdisciplinary Conference on Hypertension in Blacks, New Orleans, LA, 1/14/1996
• Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments.
  Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group, American Statistical Association Meeting, Chicago, IL, 1/4/1996
• Patient recruitment experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
  Whelton P, Cutler J, Davis B, Grimm R, Pressel S, Probstfield J, Ward H, for the ALLHAT Research Group, 16t h Scientific Meeting of the International Society of Hypertension Conference abstract monograph;, Glasgow, United Kingdom, 1/1/1996
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): update on recruitment and baseline characteristic.
  Grimm RH, Jr, Davis B, Whelton P, Pressel S, for the ALLHAT Research Group, Am J Hypertension; 11th Scientific Meeting of the American Society of Hypertension, New York, NY, 1/1/1996
• Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments.
  Davis B, Proschan M, Ford CE, for the ALLHAT Research Group, International Biometric Conference, Amsterdam, Netherlands, 1/1/1996
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Design and early baseline results.
  Grimm RH, Jr, for the ALLHAT Research Group, 11th Asian-Pacific Congress of Cardiology, Bali, Indonesia, 1/17/1995
• Selection of Clinical Sites for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
  Pressel S, Egan D, Ford C, Walsh S, Miertehin N, on behalf of the ALLHAT Research Group, Controlled Clinical Trials; 16th Annual Meeting of the Society for Clinical Trials, Seattle, WA, 1/1/1995
• Recruitment success by type of site in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Vanguard.
  Egan D, Pressel S, Davis B, on behalf of the ALLHAT Research Group, Controlled Clinical Trials; 16th Annual Meeting of the Society for Clinical Trials, Seattle, WA, 1/1/1995
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Design features.
  Davis B, for the ALLHAT Research Group, Controlled Clinical Trials; 16th Annual Meeting of the Society for Clinical Trials, Seattle, WA, 1/1/1995
• Join now to see all

Lectures

• Improving Blood Pressure Treatment in the community: How the JNC 7 Recommendation and ALLHAT results relate to your practice. 
  Methodist Hospital, Philadelphia, PA - 1/3/2006
• Aortic Stenosis-An Important Disease 
  Methodist Hospital, Philadelphia, PA - 1/15/2000
• Hypertension and Angiotensin II Receptor Antagonist (sponsored by Merck) 
  Philippino-AM Comm. Center, Philadelphia, PA - 1/26/1998
• Hypercholesterolemia-New Directions 
  Methodist Hospital, Philadelphia, PA - 1/3/1997
• Atherosclerosis and its Sequelae 
  J.C. Penny, Philadelphia, PA - 1/16/1994
• Risk Factors for Cardiovascular Disease 
  J.C. Penny, Philadelphia, PA - 1/30/1993
• Non-Invasive Assessment of Ventricular Arrhythmia 
  Franklin Square Hospital, Philadelphia, PA - 1/9/1992
• Therapy for Ventricular Arrhythmia Revisited 
  Methodist Hospital, Philadelphia, PA - 1/2/1992
• Diagnosing Heart Problems. 
  St. Agnes Medical Center, Philadelphia, PA - 1/11/1991
• Chest Pain. 
  Palumbo's Restaurant, Philadelphia, PA - 1/27/1990
• Silent Ischemia 
  Venice Plaza, Philadelphia, PA - 1/17/1990
• Ventricular Arrhythmias 
  Hilton Hotel, Mount Laurel, NJ - 1/17/1990
• Congestive Heart Failure 
  St. Agnes Medical Center, Philadelphia, PA - 1/5/1989
• Risk factors for Coronary Artery Disease. 
  St. Agnes Medical Center, Philadelphia, PA - 1/25/1988
• Hypertension-New Modalities 
  St. Agnes Medical Center, Philadelphia, PA - 1/20/1988
• Arrhythmias 
  St. Agnes Medical Center, Philadelphia, PA - 1/8/1988
• Making Sense of the New Antiarrhythmics 
  St. Joseph Medical Center, Hazelton, PA - 1/8/1987
• Dysrhythmia Management 
  St. Agnes Medical Center, Philadelphia, PA - 1/23/1985
• Be good to your heart. 
  St. Agnes Medical Center, Philadelphia, PA - 1/19/1985
• The Heart and How It Works 
  St. Agnes Medical Center, Philadelphia, PA - 1/19/1985
• Physical Auscultation. 
  St. Agnes Medical Center, Philadelphia, PA - 1/9/1985
• Successful Case of PTCA. 
  Hahnemann University - 1/4/1985
• Superventricular Tachycardia. 
  Hahnemann University - 1/4/1985
• Join now to see all